Questex

| 05.15.24 | Vaxxinity retreats from ‘abusive’ public market; Blackstone unveils Uniquity Bio with $300M

Questex sent this email to their subscribers on May 15, 2024.

Layoffs hit BioMarin, 3 biotechs

Today’s Big News

May 15, 2024

Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market 


Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential 


BioMarin sheds 170 jobs in wake of narrowed R&D refocus


Bolt Bio halves workforce and swaps out CEO, while Tenaya lays off 5th of staff


Fierce Biotech Layoff Tracker 2024: BioMarin sends 170 workers packing; Tenaya trims workforce

The Top Line Podcast: Don’t miss out on the newest episode. Listen now.

 

Featured

Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market

Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company.
 

Top Stories

Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential

Immunology and inflammation-focused drug development has become scorching hot business. This time, Uniquity Bio unveiled with $300 million from Blackstone.

BioMarin sheds 170 jobs in wake of narrowed R&D refocus

BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are also leaving the building as part of the R&D restructure.

Bolt Bio halves workforce and swaps out CEO, while Tenaya lays off 5th of staff

In another tough day for biotech employees, Bolt Biotherapeutics and Tenaya Therapeutics both outlined plans to significantly scale back their workforces.

Fierce Biotech Layoff Tracker 2024: BioMarin sends 170 workers packing; Tenaya trims workforce

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. 

After filing hitch, Eisai and Biogen begin rolling FDA submission for subcutaneous Leqembi

Late Tuesday, Biogen and Eisai said they kicked off a rolling FDA submission for the subcutaneous version of Leqembi—which is currently infused—after winning a fast track tag from the agency.  

Radyus and Dt&CRO partner to bring more South Korean biotechs to the US

Radyus Research and Dt&CRO, a South Korean preclinical contract research organization, have agreed to share resources in a deal that will help Dt&CRO’s clients enter the U.S. pharmaceutical market and give Radyus lab testing services for clients in Asia.

What's in a clinical trial name? Breaking it down with the Brand Institute, from the acronymic to the aspirational

Naming a new trial represents a significant marketing opportunity for drug and device makers well before their products ever hit shelves, especially because study monikers, unlike drug names, aren’t subject to regulatory oversight.

The White House raises tariffs on medical supplies from China

To boost domestic medical supply manufacturing, the Biden administration is hiking up tariffs on syringes, needles, medical and surgical gloves and personal protective equipment from China.
 
Fierce podcasts

Don’t miss an episode

THE TOP LINE

Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. 
 

Resources

Whitepaper

Comprehensive Cell Solutions: Focus on Cellular Therapy Collections

Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.
Whitepaper

In Vitro Antibodies – Next-Gen Science Delivers Optimized Candidates

Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.
Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.
Whitepaper

Vaccine Development Challenges in Facing Influenza and COVID-19

Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead.
eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.
Whitepaper

Patient Engagement Series

Discover the secrets behind successful patient engagement
Whitepaper

Antibody Profiling: Decoding the Humoral Immune System

Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today!

Whitepaper

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

 

Industry Events

Drug Development Boot Camp® VIRTUAL | Spring 2024

April ‌10-11, ‌2024

On Helix

Date: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UK

 

Upcoming Fierce Events

Text-only version of this email

Brand Logo A message from IQVIA Technologies IQVIA ECOA. AMPLIFYING THE PATIENT’S VOICE IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management. TODAY’S BIG NEWS May 15, 2024 Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market  ---------------------------------------------------------------------------------------------------------------------------------- Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential  ---------------------------------------------------------------------------------------------------------------------------------- BioMarin sheds 170 jobs in wake of narrowed R&D refocus ---------------------------------------------------------------------------------------------------------------------------------- Bolt Bio halves workforce and swaps out CEO, while Tenaya lays off 5th of staff ---------------------------------------------------------------------------------------------------------------------------------- Fierce Biotech Layoff Tracker 2024: BioMarin sends 170 workers packing; Tenaya trims workforce The Top Line Podcast: Don’t miss out on the newest episode. Listen now. A message from WittKieffer GG E propel YOUR MISSION FORWARD with LEADERSHIP Executive Search | Professional Search | Interim Leadership | Leadership Advisory FEATURED VAXXINITY LEADERS DETAIL RETREAT FROM 'ABUSIVE RELATIONSHIP' AFTER 3 YEARS ON PUBLIC MARKET By Annalee Armstrong Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company. TOP STORIES BLACKSTONE UNEARTHS UNIQUITY BIO WITH $300M TO EXPLORE MERCK DRUG'S I&I POTENTIAL By Max Bayer Immunology and inflammation-focused drug development has become scorching hot business. This time, Uniquity Bio unveiled with $300 million from Blackstone. BIOMARIN SHEDS 170 JOBS IN WAKE OF NARROWED R&D REFOCUS By James Waldron BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are also leaving the building as part of the R&D restructure. BOLT BIO HALVES WORKFORCE AND SWAPS OUT CEO, WHILE TENAYA LAYS OFF 5TH OF STAFF By James Waldron In another tough day for biotech employees, Bolt Biotherapeutics and Tenaya Therapeutics both outlined plans to significantly scale back their workforces. A message from Watchmaker Genomics ACCESS MORE INFORMATION FROM YOUR FFPE RNA-SEQ SAMPLES Identify more unique genes with a rapid workflow (< 5 hrs) and inputs down to 1 ng. Explore the data. FIERCE BIOTECH LAYOFF TRACKER 2024: BIOMARIN SENDS 170 WORKERS PACKING; TENAYA TRIMS WORKFORCE By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.  AFTER FILING HITCH, EISAI AND BIOGEN BEGIN ROLLING FDA SUBMISSION FOR SUBCUTANEOUS LEQEMBI By Fraiser Kansteiner Late Tuesday, Biogen and Eisai said they kicked off a rolling FDA submission for the subcutaneous version of Leqembi—which is currently infused—after winning a fast track tag from the agency.   RADYUS AND DT&CRO PARTNER TO BRING MORE SOUTH KOREAN BIOTECHS TO THE US By Helen Floersh Radyus Research and Dt&CRO, a South Korean preclinical contract research organization, have agreed to share resources in a deal that will help Dt&CRO’s clients enter the U.S. pharmaceutical market and give Radyus lab testing services for clients in Asia. WHAT'S IN A CLINICAL TRIAL NAME? BREAKING IT DOWN WITH THE BRAND INSTITUTE, FROM THE ACRONYMIC TO THE ASPIRATIONAL By Andrea Park Naming a new trial represents a significant marketing opportunity for drug and device makers well before their products ever hit shelves, especially because study monikers, unlike drug names, aren’t subject to regulatory oversight. THE WHITE HOUSE RAISES TARIFFS ON MEDICAL SUPPLIES FROM CHINA By Heather Landi To boost domestic medical supply manufacturing, the Biden administration is hiking up tariffs on syringes, needles, medical and surgical gloves and personal protective equipment from China. Fierce podcasts DON’T MISS AN EPISODE THE TOP LINE FULFILLING THE PROMISE OF CELL & GENE THERAPIES THROUGH MANUFACTURING (PART I) This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing.  A DEEP DIVE INTO HEALTH SYSTEM AND HEALTH PLAN Q1 EARNINGS A CLOSER LOOK AT 2023'S TOP BIOPHARMA DEALS AND WHAT LIES AHEAD A message from Promab Biotechnologies Chimeric Antigen Receptor Englneerlng \v\\\ . PeSe ProMab Biotechnologies, Inc. Vlral . Llpld Nanopartlcle Based C&@’ Dellvery o |dentifying & Validating Biomarkers o CAR Design & Vector Creation CAR In Vitro Assays © Antibody scFv Generation © Gene Packaging & Delivery CAR In Vivo Assays RESOURCES Whitepaper COMPREHENSIVE CELL SOLUTIONS: FOCUS ON CELLULAR THERAPY COLLECTIONS Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions Whitepaper IN VITRO ANTIBODIES – NEXT-GEN SCIENCE DELIVERS OPTIMIZED CANDIDATES Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company Whitepaper BRANDED DIGITAL COMPANIONS IN BIOPHARMA This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences Whitepaper VACCINE DEVELOPMENT CHALLENGES IN FACING INFLUENZA AND COVID-19 Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services eBook DESIGNING PATIENT-CENTERED ENDPOINT IN RARE DISEASE TRIALS To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company Whitepaper PATIENT ENGAGEMENT SERIES Discover the secrets behind successful patient engagement Sponsored by: ProofPilot Whitepaper ANTIBODY PROFILING: DECODING THE HUMORAL IMMUNE SYSTEM Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today! Sponsored by: Sengenics Corporation LLC Whitepaper STRAIGHT TO MARKET IN AN AUTOINJECTOR The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by: Lonza INDUSTRY EVENTS Drug Development Boot Camp® VIRTUAL | Spring 2024 April ‌10-11, ‌2024 On Helix Date: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UK UPCOMING FIERCE EVENTS 13-15 May Digital Pharma Engage Newport Beach, CA 14-15 May Pharma PR & Communications Summit West Newport Beach, CA 21-23 May Digital Pharma Innovation Week Free Virtual Event 30 May Fierce Pharma Forward: Drug Development and Delivery Insights for 2024 Free Virtual Event 8-9 Jul Pharma PR & Communications Summit East Jersey City, NJ View all events Brand Logo Linkedin LogoFacebook LogoTwitter LogoYoutube Logo  Connect Advertise Contact Subscriptions Contact Support Our team Senior Editor: Annalee Armstrong UK/EU Bureau Chief: James Waldron Staff Writers: Max Bayer, Gabrielle Masson Contributing Writer: Nick Paul Taylor Editor-in-Chief: Ayla Ellison Publisher: Rebecca Willumson Group Sales Director: Angelique Alcover This email was sent to [email protected] as part of the Fierce Biotech email list. /\\f SRS RIS RO K/ %J&j& L\
Show all

The Latest Emails Sent By Questex

More Emails, Deals & Coupons From Questex

Email Offers, Discounts & Promos From Our Top Stores